Archemix, BaroFold, Mirus, Pfizer deal

By WIR Staff | Jan 15, 2007 | 8:00 AM GMT

Archemix will use its SELEX discovery technology to identify aptamers for three undisclosed targets from PFE. PFE will develop and commercialize the compounds for undisclosed indications. Archemix will receive an undisclosed upfront

Read the full 328 word article

How to gain access

Continue reading with a
two-week free trial.